

A REVIEW ON THE IMPORTANCE OF HAEMATOLOGICAL MARKERS IN RELATION TO TYPE 2 DIABETES MONITORING

ABSTRACT

Diabetes mellitus is a chronic disease that occurs when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin that it produces. The most common type of diabetes is type II diabetes, which is characterized by insulin resistance or relative insulin deficiency. Diabetes mellitus shows a significant derangement in various hematological parameters such as RBC, platelet, WBC, Red cell indices and RDW. Routine screening of blood cell parameters in poorly controlled T2DM gives an awareness about further complication and should be helpful for regular management of T2DM. This review analyzes the predictive power of hematological parameters for T2DM.

Keywords: Diabetes Mellitus, HBA1C- Glycated Hemoglobin, Hyper Glycemic Index, RBC Indices

ABBREVIATIONS

<i>CBC:</i>	<i>Complete Blood Count</i>
<i>T2DM:</i>	<i>Type 2 Diabetic Mellitus</i>
<i>FBS:</i>	<i>Fasting Blood Sugar</i>
<i>RBS:</i>	<i>Random Blood Sugar</i>
<i>OGTT:</i>	<i>Oral Glucose Tolerance Test</i>
<i>MCV:</i>	<i>Mean Corpuscular Volume</i>
<i>MCH:</i>	<i>Mean Corpuscular Hemoglobin</i>
<i>MCHC:</i>	<i>Mean Corpuscular Hemoglobin Concentration</i>
<i>RDW:</i>	<i>Red cell Distribution Width</i>

1. INTRODUCTION

Diabetes mellitus is a chronic disease associated with the inability to produce an adequate amount of hormone insulin or to effectively use the insulin produced by the body [1]. It is a diverse set of disorders defined by different abnormalities in the control of protein, lipid, or carbohydrate metabolism [2]. Uncontrolled blood glucose levels have been associated with a number of conditions that can cause disability, such as cardiovascular disease, nerve damage that can result in different types of neuropathies and kidney damage that can lead to diabetic nephropathy, diabetic foot that can

cause a drop in body temperature, and ocular diseases that primarily affect the retina and cause blindness and vision loss [3].

Long-term exposure to high glucose causes hemoglobin to be glycated by enzymes, and membrane proteins cause the aging of red blood cells, which may eventually cause hyperlipemia with a lower red blood cell count. A different process might result from a change in the fluid electrolyte balance. In T2DM patients with high blood glucose, the activity of the erythrocyte membrane cation pump protein is impaired [4].

The most widely used laboratory tests for screening and tracking blood glucose levels are HbA1C, OGTT, and FBS [5]. The HbA1C blood test indicates a patient's average blood glucose level during the previous two to three months, or the predicted life span of red blood cells [6]. The best use of HbA1C as a biomarker is for long-term blood glucose monitoring. In contrast to other glucose-based tests, it is not as affected by variables like dietary consumption, stress levels, physical activity, and immediate treatment response [7,56,57,58,59].

A complete blood count consists of a panel of tests that are typically used to differentiate between

various forms of anemia. RBC parameters include MCV, MCH, MCHC, RDW, hemoglobin, hematocrit, and red blood cell count[8]. One potential cause of elevated RDW in T2DM patients could be hyperglycemia-induced oxidative damage and chronic inflammation. A high intracellular glucose concentration brought on by an influx of glucose to the erythrocyte via the insulin-dependent glucose transporter (GLUT1) may be the cause of an increased MCV in patients with poor glycemic control. This rapid diffusion of water into the cell flattens the biconcave disk and bloats the cell [8,9].

Even though HBA1C is still the gold standard for evaluating long-term glycemic management, poor nations have limited access due to the high cost of this test when it comes to routine diagnostic care[10]. Red cell characteristics that can be utilized to track the course of complications and diabetes control are the primary focus of this review. Thereby making them a valuable tool for the assessment of T2DM patients[11].

Therefore, the goal of the study is to assess red blood cell characteristics for monitoring type 2 diabetes patients. Our findings may help with T2DM management in the future.

2.INSULIN RESISTANT DIABETES MELLITTUS

Diabetes mellitus is a type of metabolic disease characterized by elevated blood sugar levels, which are typically caused by abnormalities in insulin secretion, flow, or both. Because of hyperinsulinemia, the body's cells and tissues are not receiving enough insulin, which leads to irregularities in the metabolism of fat, protein, and carbohydrates. Insulin-dependent diabetes mellitus (type 1) and non-insulin-dependent diabetes mellitus (type 2) are the two main forms of diabetes. Reduced insulin secretion will prevent glucose from entering the cell, which will cause hyperglycemia. It is possible for insulin to reduce hyperglycemia[13].

Type 2 diabetes mellitus is the most prevalent type of disease in adults. It is a long-term metabolic illness characterized by low insulin synthesis or insulin resistance, both of which raise blood sugar levels[14]. Chronic hyperglycemia causes a number of physiological and pathological processes, such as oxidative stress, which impacts

lipid metabolism, inflammatory response, cell growth, immunological, and hematological parameters, all of which are evident in patients with poorly controlled diabetes[15].Increasedoxidative stress causes hematological changes that impact platelets, WBCs, and RBCs in terms of their structure, function, and metabolism[16].

The primary cause of end-stage renal disease is diabetes mellitus, and a significant number of patients with diabetes mellitus experience renal complications[17].

Diabetes patients experience anemia twice as frequently as non-diabetics. When comparing individuals with diabetes nephropathy to those with nephropathy from other causes, the risk of anemia is increased[18]. Chronic hyperglycemia associated with diabetes may cause a hypoxic environment in the renal interstitium, which will reduce erythropoietin synthesis [19]

An increased leukocyte count relates to the presence of neuropathy and vasculopathy by accumulation of blood glucose which block the blood vessels or nerves [20].

It's crucial to remember that patients with diabetes are more atherogenic from dyslipidemia than people without the disease. Dyslipidemia, hypertension, and altered hematological indicators are all components of the metabolic syndrome, which includes type 2 diabetes[21].

In diabetes, macrovascular and microvascular complications are the main cause of death rather than cardiovascular disease[22,23]. The disease known as atherosclerosis is inflammatory. Nearly every blood component, including platelets, WBCs and RBCs has a part in the underlying pathophysiology of atherosclerosis[24]. It's critical to achieve HBA1C range optimization of 6.5–7%[25]. Glycated protein, urine sugar, fructosamine, glycated hemoglobin (HbA1C), urine protein such as micro albuminuria, glucose level in plasma (random sample), and urine sugar are among the laboratory tests used to monitor patients with diabetes mellitus[26,27]. Increased HbA1C is positively related to the longer duration of type 2 diabetes[28].

3.ASSOCIATION OF BLOOD CELL PARAMETERS IN DIABETES MELITTUS

The complete blood count, which consists of a panel of analytical tests typically used to distinguish RBC characteristics[29,30]. The metrics associated with red blood cells are as follows: the number of red blood cells, the hematocrit, the hemoglobin, the mean corpuscular volume, the mean corpuscular hemoglobin concentration, and the red cell distribution width[31,32].

3.1 RBC COUNT

Diabetes patients with HbA1C >7 have significantly lower red blood cell counts, hemoglobin levels, and hematocrit levels, which suggests that anemia is more likely to develop in people with diabetes [33, 34]. Chronic exposure to high glucose causes non-enzymatic glycation of membrane protein and hemoglobin [35], which ages red blood cells and ultimately lowers the RBC count in patients with persistent hyperglycemia [36].

3.2 Red cell indices

Many studies have shown a relationship of RBC indices and HbA1C [37,38]. While mean corpuscular hemoglobin and mean corpuscular hemoglobin concentration characterize the hemoglobin content of RBC, mean corpuscular volume shows the size of RBC[39,40]. Hyperglycemia affects red blood cell aggregation and deformability and shortens its lifespan [41]. MCV and MCH were significantly increase in T2DM but no significance of MCHC [42]

3.3 Red cell distribution width

RDW is a measurement of size variation among circulating red cells and is calculated as part of routine CBC. The RDW along with mean cell volume, is useful in the differential diagnosis of anemia [43, 44]. It can be used as a biomarker that is simple to measure and may help to identify diabetes mellitus. It had a strong positive correlation with HbA1C [45].

3.4 Hemoglobin concentration

Hemoglobin and diabetes profiles are closely related. Blood viscosity is also significantly influenced by hemoglobin levels [46].

3.5 WBC count

A high systemic neutrophil count is related with the presence and severity of diabetes [47]. Leukocyte count can indicate the overall inflammatory state of the body [48].

3.6 Hematocrit

There is a correlation between hematocrit and length of diabetes, body weight in patients with HbA1C >7 [49].

3.7 Platelet function

Blood platelets are essential to the process of blood coagulation. There have been reports of altered platelet shape and function in diabetes patients. Insulin resistance in T2DM has been linked to a platelet disorder caused by insulin action. The entire coagulation cascade is defective in T2DM [50]. An increase in mean platelet volume may indicate the development of atherosclerosis, which is associated with diabetes and vascular complications [51].

Type 2 diabetes mellitus is a fundamental public health problem that has been increasing dramatically worldwide[52]. Inappropriate control of blood glucose in diabetes patients is the main key to the incidence of both micro and macrovascular problems[53]. Glycation of hemoglobin and membrane proteins causes persistent hyperglycemia in diabetes, which is linked to metabolic, structural, and functional alterations in red blood cells. Moreover, endothelial tissue damage and RBC malfunction are linked to elevated levels of oxygen free radical generation and chronic inflammation[54]. In addition, RBC glycation causes increased aggregation and decreased deformities because it decreases membrane fluidity[55].

4. CONCLUSION

This review states the role of haematological parameters in managing T2DM. Haematological alteration among diabetes can lead to long term complication and even death. CBC is a low cost, standard, easy test that provide significant result. This suggest that regular CBC examination is necessary for early identification and treatment of diabetes patient in primary care settings. Hence

haematological parameter has a crucial role in understanding progression of disease and further improve the quality of life.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Author(s) hereby declares that generative AI technologies such as Large Language Models, etc have been used during writing or editing of manuscripts. This explanation will include the name, version, model, and source of the generative AI technology and as well as all input prompts provided to the generative AI technology

Details of the AI usage is given below:

1. Quilibolt
2. Grammarly

REFERENCES

1. Meshesha M, Melke A, Ajema A, Mayisso K. Evaluation of Red Blood Cell Indices for Prediction of Glycemic Control in People Living with Type 2 Diabetes. *Diabetes, Metabolic Syndrome and Obesity*. 2024 Feb 1; Volume 17:619–32.
2. Marcovecchio L. Complications of acute and chronic hyperglycemia. *US Endocrinol*. 2017;13(1):17–21. doi:10.17925/use.2017.13.01.17
3. Kumari N, Singh JK, Prasad K. Assessment of red blood cell parameters as a biomarker for glycaemic control in patients of Type 2 Diabetic mellitus: a Cross-Sectional Study. *International Journal of Pharmaceutical Sciences Review and Research*. 2023 Apr 1;79(2).
4. M A, T S, K K, M FB, M T, B Z. Evaluation of red blood cell parameters as a biomarker for Long-Term Glycemic Control monitoring among Type 2 diabetic patients in Southwest Ethiopia: A Cross-Sectional study. *Diabetes, Metabolic Syndrome and Obesity*. 2021 Dec 1; Volume 14:4993–5000.
5. Gribovschi M. The methodology of glucose monitoring in type 2 diabetes mellitus. *NutrMetab Dis*. 2013;86(2):93–96
6. Leow MKS. Glycated hemoglobin (HbA1c): clinical applications of a mathematical concept. *Acta Inform Med*. 2016;24(4):233–238. doi: 10.5455/aim.2016.24.233-238
7. Saudek CD, Kalyani RR, Derr RL. Assessment of glycemia in diabetes mellitus: hemoglobin A1c. *J Assoc Physicians India*. 2015; 53:299–305.
8. Dada OA, Uche E, Akinbami A, Odesanya M, John-Olabode S, Adediran A, et al. The relationship between red blood cell distribution width and blood pressure in patients with type 2 diabetes mellitus in Lagos, Nigeria. *Journal of Blood Medicine*. 2014 Sep 1;185
9. Li Q. Hemoglobin A1C level higher than 9.05% causes a significant impairment of erythrocyte deformability in diabetes mellitus. *ActaEndocrinologica*. 2018 Jan 1;14(1):66–75.
10. Park PH, Pastakia SD. Access to Hemoglobin A1c in Rural Africa: A Difficult Reality with Severe Consequences. *Journal of Diabetes Research*. 2018 Feb 26; 2018:1–5
11. Camara A, Baldé NM, Sobngwi-Tambekou J, Kengne AP, Diallo MM, Tchatchoua APK, et al. Poor glycemic control in type 2 diabetes in the South of the Sahara: The issue of limited access to an HbA1c test. *Diabetes Research and Clinical Practice*. 2015 Apr 1;108(1):187–92
12. Narjis M, Noreen M, Safi SZ, Ilahi NE, Alomar SY, Alkhouriji AF. Cross talk between complete blood count and progression of type II diabetes mellitus. *Journal of King Saud University Science/MağallaġĀmi'at Al-malikSa'ūd al-'Ulūm*. 2021 Sep 1;33(6):101492.
13. Doig K, Zhang B. A methodical approach to interpreting the red blood cell parameters of the complete blood count. *Am Soc Clin Lab Sci*. 2017;30(3):173–185.
14. Essawi K, Dobie G, Shaabi M, Hakami W, Saboor M, Madkhali A, et al. Comparative analysis of red blood cells, white blood cells, platelet count, and indices in Type 2 diabetes mellitus patients and normal controls: association and clinical implications. *Diabetes, Metabolic Syndrome and Obesity*. 2023 Oct 1; Volume 16:3123–32.
15. Sobczak AIS, Stewart AJ. Coagulatory defects in Type-1 and Type-2 diabetes. *International Journal of Molecular Sciences [Internet]*. 2019 Dec 16;20(24):6345.

16. Twig G, Afek A, Shamiss A, et al. White blood cells count and incidence of type 2 diabetes in young men. *Diabetes Care*. 2013;36(2):276–282.
17. Sobczak AIS, Stewart AJ. Coagulatory defects in Type-1 and Type-2 diabetes. *International Journal of Molecular Sciences*. 2019 Dec 16;20(24):6345.
18. Anemia in Patients with Diabetes Mellitus: Prevalence and Progression. *General Medicine*. 2014 Jan 1;03(01).
19. Badar A, Kaatabi H, Bamosa A, Al-Elq A, Abou-Hozafa B, Lebda F, et al. Effect of *Nigella sativa* supplementation over a one-year period on lipid levels, blood pressure and heart rate in type-2 diabetic patients receiving oral hypoglycemic agents: nonrandomized clinical trial. *Annals of Saudi Medicine/Annals of Saudi Medicine*. 2017 Jan 1;37(1):56–63.
20. Adane T, Getaneh Z, Asrie F. <p>Red Blood Cell Parameters and Their Correlation with Renal Function Tests Among Diabetes Mellitus Patients: A Comparative Cross-Sectional Study</p> Diabetes, Metabolic Syndrome and Obesity [Internet]. 2020 Oct 1; Volume 13:3937–46. Available from: <https://doi.org/10.2147/dms0.s275392>
21. Biadgo B, Melku M, Abebe SM, Abebe M. Hematological indices and their correlation with fasting blood glucose level and anthropometric measurements in type 2 diabetes mellitus patients in Gondar, Northwest Ethiopia. *Diabetes, Metabolic Syndrome and Obesity*. 2016 Mar 1;91.
22. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed with Type 2 Diabetes. *Diabetes Care* 2004; 27:17–20.
23. Matheus a S, Tannus LR, Cobas R a, et al. Impact of diabetes on cardiovascular disease: an update. *Int J Hypertens*2013; 2013:653789.
24. Kizilgul M, Sencar E, Ucan B, Beysel S, Ozcelik O, Ozbek M, et al. Components of the Complete Blood Count in Type 2 Diabetes Mellitus with Inadequate Glycemic Control. *Dicle Tip Dergisi [Internet]*. 2018 Jun 15;45(2):113–20.
25. A.Ziaee, A. et al. Association of hematological indices with prediabetes: A cross-sectional study. *Electronic Physician*. (2017). 9(9): 5206–11.
26. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease. *Circulation*. 1999 Sep 7;100(10):1134–46.
27. American diabetes association (ADA). Available at: <http://www.ndei.org>, <http://www.diabetes.org> (Last accessed on June 15, 2017).
28. ES. Kilpatrick, AS. Rigby, SL. Atkin. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. *Diabetes Care*. (2008). 31(11): 2198–202.
29. Rahbar S, Blumenfeld O, Ranney HM. Studies of an unusual hemoglobin in patients with diabetes mellitus. *BiochemBiophys Res Commun*. 1969; 36: 838–43.
30. Salhen Al, Khaled S, Mahmoud, Ameerah Y. Hematological profile of patients with type 2 Diabetic mellitus in El-Beida, Libya. *Ibnosina J Med Biomed Sci*. 2017;9(3):76–80.
31. Badedi M, Solan Y, Darraj H, Sabai A, Mahfouz M, Alamodi S, et al. Factors associated with long-term control of type 2 diabetes mellitus. *J Diabetes Res* 2016; 2016:2109542.
32. Salhen Al, Khaled S, Mahmoud, Ameerah Y. Hematological profile of patients with type 2 Diabetic mellitus in El-Beida, Libya. *Ibnosina J Med Biomed Sci*. 2017;9(3):76–80.
33. Farooqui R, Afsar N, Afroze IA. Role and Significance of Hematological parameters in Diabetes Mellitus. *Annals of Pathology and Laboratory Medicine*. 2019 Mar 16;6(3): A158-162.
34. Jeffcoate SL. Diabetes control and complications: the role of glycated haemoglobin, 25 years on. *Diabet Med*.2004; 21: 657–65.
35. Szwegold BS, Howell SK, Beisswenger PJ. Nonenzymatic glycation / enzymatic deglycation: a novel hypothesis on the etiology of diabetic complications. *IntCongr Ser*. 2002; 1245: 143–52.
36. Goldstein DE, Little RR, Lorenz RA et al. Tests of glycemia in diabetes. *Diabetes Care*. 2004; 27: 1761–73.
37. Gould BJ, Davie SJ, Yudkin JS. Investigation of the mechanism underlying the variability of glycated A1c in the management of diabetes.
38. American Diabetes Association. Standards of medical care in diabetes 2008. *Diabetes Care*. 2008; 31(Suppl. 1): S12–54.

39. Asmamaw M, Sime T, Kene K, Baye MF, Teshome M, Zawdie B. Evaluation of red
40. blood cell parameters as a biomarker for long-term glycemic control monitoring among type 2 diabetic patients in Southwest Ethiopia: a cross-sectional study. *DiabetMetaboSyndObes.* 2021; 14:4993. doi:10.2147/DMSO.S348907
41. Bhutto AR, Abbasi A, Abro AH. Correlation of hemoglobin A1c with red cell width distribution and other parameters of red blood cells in type II diabetes mellitus. *Cureus.* 2019; 11:8.
42. Sarma PR. Red cell indices. *Clinical Methods.* 1990; 1990:1.
43. Virtue MA, Furne JK, Nuttall FQ, Levitt MD. Relationship between GHb concentration and erythrocyte survival determined from breath carbon monoxide concentration. *Diabetes Care.* 2004;27(4):931–935. doi:10.2337/diacare.27.4.931.
44. Finucane K, Ambrey P, Narayan S, Archer CB, Dayan C. Insulin injection abscesses caused by *Mycobacterium chelonae*. *Diabetes Care [Internet].* 2003 Aug 1;26(8):2483–4. Available from: <https://doi.org/10.2337/diacare.26.8.2483>
45. L. Guariguata. By the numbers: New estimates from the IDF Diabetes Atlas Update for. *Diabetes Res ClinPract.* (2012). 98:524–5.
46. CE. Koro, et al. Glycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed with Type 2 Diabetes. *Diabetes Care.* (2004). 27:17–20.
47. M, N., D, J., & D, K. (2017). Study of relationship between WBC count and Diabetic complications. *International Journal of Medicine,* 4(4), 1128. <https://doi.org/10.18203/2349-3933.ijam20173245>
48. Jiang H, Yan W, Li C, Wang A, Dou J, Mu Y. Elevated white blood cell count is associated with higher risk of glucose metabolism disorders in middle-aged and elderly Chinese people. *Int J. Environ Res Pub Health.* 2014; 11:5497-5509.
49. Jiang H, Yan W, Li C, Wang A, Dou J, Mu Y. Elevated white blood cell count is associated with higher risk of glucose metabolism disorders in middle-aged and elderly Chinese people. *Int J. Environ Res Pub Health.* 2014; 11:5497-5509.
50. Demirtas L, Degirmenci H akbasem, Ozcicek A, Timuroglu A, Gurel A, OzcicekF. Association of hematological indices with diabetes, impaired glucose regulation and microvascular complications of diabetes. *Int J Clin Exp Med.* 2015;8(7):11420–7.
51. Duman E, Kulaksizoglu S, Cifci E, OzulkuM. Is there a real correlation between red cell distribution width and peripheral arterial disease? *J Med Biochem.* 2017; 36:309–13.
52. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. (2005). Atherothrombosis and high-risk plaque: part I: evolving concepts. *J Am Coll Cardiol,*46(6):937– 54.
53. Asmah RH, Yeboah G, Archampong TN, Brown CA, Amegatcher G, Adjei DN. Relationship between oxidative stress and haematological indices in patients with diabetes in the Ghanaian population. *Clin Diabetes Endocrinol.* 2015;1(7):4–8. doi:10.1186/s40842-015-0008-2
54. Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insightsand therapeutic strategies. *CardiovascDiabetol.* 2018;17(121):1–17. doi:10.1186/s12933-018-0763-3
55. Sobczak AIS, Stewart AJ. Coagulatory defects in Type-1 and Type-2 diabetes. *International Journal of Molecular Sciences.* 2019 Dec 16;20(24):6345.
56. Lakhani, Jitendra D., Hetal Pandya, Archit Jain, and SachinGhadiya. 2020. “Continuous Blood Glucose Monitoring to Determine the Glycemic Variability in Patients Having SARS CoV-2 Infection With ARDS and Its Bearing on the Severity of the Disease”. *Journal of Advances in Medicine and Medical Research* 32 (16):51-56. <https://doi.org/10.9734/jammr/2020/v32i1630629>.
57. Albalawi, M. S. D., Alamer, Z. A. H., Alkhars, F. S. H., Alshuhayb, B. S. A., Alqasim, A. J. A., Alomar, N. O. S., Alessa, J. A. S., Alhamad, F. A. S., Aljohani, L. M. R. and Alotaibi,

M. A. R. (2021) "Self-Monitoring Blood Glucose Method and Outcome: A Review", *Journal of Pharmaceutical Research International*, 33(57B), pp. 8–14. doi: 10.9734/jpri/2021/v33i57B34022

58. Vashist SK. Non-invasive glucose monitoring technology in diabetes

management: A review. *Analyticachimicaacta*. 2012 Oct 31;750:16-27.

59. Muchmore DB, Springer J, Miller M. Self-monitoring of blood glucose in overweight type 2 diabetic patients. *Actadiabetologica*. 1994 Dec;31:215-9.

UNDER PEER REVIEW